Micreos is a platform biotech company focused on discovering and developing recombinant proteins for chronic Dermatology / Oncology conditions. Micreos is a clinical-stage pharmaceutical biotech developing medicinal solutions that selectively kill only harmful bacteria while preserving the rest of the health-enhancing microbiome. Our vision is to positively impact patient care while helping global health care systems to address impending anti-microbial resistance (AMR) concerns. Our unique capability in modular engineering to optimize enzyme therapeutics means that we have already developed three endolysin-based investigational antimicrobials. These antimicrobials are focused on the detrimental impact of Staphylococcus aureus (S. aureus) in oncology, dermatology and bloodstream infections.
Something looks off?